A case of erythroderma with elevated serum immunoglobulin E and thymus and activation‐regulated chemokine levels following coronavirus disease 2019 vaccination

Iwasawa, Okuto; Okada, Hirofumi; Komine, Mayumi; Ohtsuki, Mamitaro

doi:10.1111/1346-8138.16257

Cited by 4 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 164 non‐injection‐site reactions in 161 patients have been reported in previous case reports and series 7–88 . Patients with systemic lupus erythematosus (SLE) and lupus erythematosus profundus (LEP) showed exacerbation of lupus eruptions after 2 weeks, and other AEs developed several months later.…”

Section: Resultsmentioning

confidence: 99%

Cutaneous adverse events following COVID‐19 vaccination: A case series of 30 Japanese patients and a review of 93 Japanese studies

Baba,

Yamada,

Kanekura

2024

The Journal of Dermatology

View full text Add to dashboard Cite

In Japan, cutaneous adverse events (AEs) following the coronavirus disease 2019 (COVID‐19) vaccination have been frequently described; however, a larger case series and literature review are lacking. There is an urgent need for an extensive investigation of new cases and previous reports to provide a thorough body of information about post‐COVID‐19 immunization cutaneous AEs. We aimed to analyze patients with cutaneous AEs after COVID‐19 vaccination in our hospital and review previous studies of cutaneous AEs. We analyzed post‐COVID‐19 vaccination cutaneous AEs in our department, the Japanese Registry, and previous literature. We enrolled 30 patients with cutaneous post‐vaccination AEs in our department over 2 years (April 1, 2021, to March 31, 2023). We also confirmed cases registered in the Ministry of Health, Labor, and Welfare COVID‐19 vaccine side effect reporting system (February 17, 2021–March 12, 2023). A total of 587 records were retrieved and 93 articles were included for data extraction. A total of 28 non‐injection‐site cutaneous AEs and two injection‐site AEs were identified. Six (20.0%) patients developed new‐onset erythematous eruptions, and five (16.7%) patients developed urticaria. Pruritic eruption, eczema, shingles, and sweating symptoms have also been reported. In previous studies on non‐injection‐site cutaneous AEs, individuals who received the BNT162b2 vaccine were older than those who received mRNA‐1273 (P < 0.01). Cutaneous AEs were mostly nonsignificant and self‐limiting reactions; however, rare, severe, or life‐threatening AEs were also reported. Physicians should be aware of the various possible cutaneous AEs associated with the COVID‐19 vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

Cutaneous adverse events following COVID‐19 vaccination: A case series of 30 Japanese patients and a review of 93 Japanese studies

Baba,

Yamada,

Kanekura

2024

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…Erythroderma is diffuse erythema and scaling involving a majority of the skin. While there were many case reports of flare-up in patients with previously diagnosed psoriatic or eczematous erythroderma, there is little literature on new-onset erythroderma in COVID-19-positive patients [ 61 , 62 ].…”

Section: Cutaneous Reactions To Sars-cov-2 Infectionsmentioning

confidence: 99%

Viruses, Variants, and Vaccines: How COVID-19 Has Changed the Way We Look at Skin

Singh

Freeman

2022

Curr Derm Rep

View full text Add to dashboard Cite

Purpose of Review This review aims to evaluate the spectrum of cutaneous reactions after both SARS-CoV-2 infection and COVID-19 vaccination while simultaneously understanding the evolution of the field of dermatology in the face of an ongoing pandemic. Recent Findings The most commonly reported cutaneous reactions after COVID-19 infection in the literature to date include morbilliform or maculopapular rashes, chilblains, and urticaria. The incidence of cutaneous reactions after COVID-19 vaccination was 9% in larger cohort studies and more commonly occurred after mRNA-based COVID-19 vaccines than adenovirus vector vaccines. The most frequently reported cutaneous reactions after COVID-19 vaccines were delayed large local reactions, local injection site reactions, urticarial eruptions, and morbilliform eruptions. Summary With the ongoing pandemic, and continued development of new COVID-19 variants and vaccines, the landscape of cutaneous reactions continues to rapidly evolve. Dermatologists have an important role in evaluating skin manifestations of the virus, as well as discussion and promoting COVID-19 vaccination for their patients.

show abstract

“…Both were elderly, required systemic corticotherapy and presented a late (15–30 days) resolution. Erythroderma following mRNA vaccine was related, 8 but there are no reports associating this condition to ChAdOx1 vaccine. Cutaneous reactions associated to COVID‐19 vaccination are mostly mild to moderate, oligosymptomatic and self‐limited.…”

Section: Figurementioning

confidence: 99%

Rare cutaneous reactions after ChAdOx1 (Oxford‐AstraZeneca) vaccine: 12 case series from Brazil

Seque

Enokihara

Nascimento

et al. 2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

A case of erythroderma with elevated serum immunoglobulin E and thymus and activation‐regulated chemokine levels following coronavirus disease 2019 vaccination

Cited by 4 publications

References 4 publications

Cutaneous adverse events following COVID‐19 vaccination: A case series of 30 Japanese patients and a review of 93 Japanese studies

Cutaneous adverse events following COVID‐19 vaccination: A case series of 30 Japanese patients and a review of 93 Japanese studies

Viruses, Variants, and Vaccines: How COVID-19 Has Changed the Way We Look at Skin

Rare cutaneous reactions after ChAdOx1 (Oxford‐AstraZeneca) vaccine: 12 case series from Brazil

Contact Info

Product

Resources

About